Auditor Resigns at CTT Pharma Amid Going-Concern Warning
CTTH has more than doubled off its 52-week low of $0.025.
Summary
CTT Pharma's auditor resigned effective October 2, 2026, and will not complete the 2026 audit. The company cites no accounting disagreements, but the departure adds governance risk to a company already facing a going-concern warning and $31 in cash.
Key Events · Corporate Governance and Compliance · CTTH
-
Auditor Resignation
Holt & Patterson, LLC resigned as independent auditor effective October 2, 2026, and will not complete the audit for the year ended December 31, 2026.
-
No Accounting Disagreements
The company states there were no disagreements on accounting practices; the auditor is exiting SEC reporting clients entirely.
-
Outstanding Fees
The auditor's resignation letter notes $4,825 in outstanding professional fees remain due from CTT Pharma for the 2025 audit.
-
Going-Concern Context
The resignation follows the Q2 2026 10-Q disclosing a going-concern warning, $31 in cash, and two material weaknesses in internal controls.
Analysis · CTTH · Life Sciences
Holt & Patterson, LLC resigned as CTT Pharma's independent auditor effective October 2, 2026, and will not complete the audit for the year ended December 31, 2026. The company states there were no disagreements on accounting practices — the auditor is simply exiting SEC reporting clients. This lands on a company already under severe financial stress: the Q2 2026 10-Q disclosed a going-concern warning, only $31 in cash, and two material weaknesses in internal controls. Losing an auditor mid-cycle forces the company to find a replacement quickly, which can delay filings, trigger compliance risk, and add costs it can ill afford. The $4,825 in outstanding audit fees underscores how tight cash is. For a micro-cap trading at $0.0566, this is a meaningful governance red flag.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTTH was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $0.03 to $0.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.